

Supplementary Table 1. Change in serum 25(OH)D level within treatment groups

	Total (N=91)	Raloxifene monotherapy group (N=44)	Raloxifene/vitamin D combina- tion therapy group (N=47)
Serum 25(OH)D level (ng/mL) at baseline	25.2 ± 9.6	23.1 ± 9.7	27.1 ± 9.2
Serum 25(OH)D level (ng/mL) at week 8	25.4 ± 8.4	21.6 ± 9.0	28.9 ± 6.0
Serum 25(OH)D level (ng/mL) at week 16	25.7 ± 8.1	21.4 ± 8.3	29.8 ± 5.4
Change in serum 25(OH)D level (ng/mL) from baseline to week 8	0.2 ± 5.5	-1.5 ± 4.7	1.8 ± 5.8
Corrected <i>P</i> -value ^{a)}	1.0000	0.1286	0.1146
Change in serum 25(OH)D level (ng/mL) from baseline to week 16	0.6 ± 6.7	-1.7 ± 6.2	2.7 ± 6.5
Corrected <i>P</i> -value ^{a)}	1.0000	0.2389	0.0192
Change in serum 25(OH)D level (ng/mL) from week 8 to week 16	0.4 ± 4.2	-0.2 ± 4.8	0.9 ± 3.6
Corrected <i>P</i> -value ^{a)}	1.0000	1.0000	0.7410

The data is presented as mean ± standard deviation and compared using the paired *t*-test or Wilcoxon signed rank test.

^{a)}Corrected *P*-value = *P*-value with Bonferroni's correction (level = 3).

25(OH)D, 25-hydroxy-vitamin D.